CLDN5 and central nervous system cancer: In glioma ECs, upregulation of miR-181a targeted Kruppel-like factor 6 (KLF6), downregulating ZO-1, occluding, and claudin-5, and increased permeability of the blood-tumor barrier (BTB) [10].